Press release
Metastatic Colorectal Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Discover the latest drugs and treatment options in the Metastatic Colorectal Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Metastatic Colorectal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
* In October 2024:- Buzzard Pharmaceuticals- A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination with Pembrolizumab in Patients with Metastatic or Unresectable, Locally Advanced Colorectal Cancer. In this study the investoigators are testing a new type of immunotherapy aclled isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this otherwise effective treatment to work on this treatment resistant type of tumor.
* In October 2024:- AbbVie- An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer.
* DelveInsight's Metastatic Colorectal Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Metastatic Colorectal Cancer treatment.
* The leading Metastatic Colorectal Cancer Companies such as Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech, and others.
* Promising Metastatic Colorectal Cancer Therapies such as Encorafenib, Cetuximab, NPX267, MRTX849, Cetuximab, TNO155, BXQ-350 , and others
Stay ahead with the most recent pipeline outlook for Metastatic Colorectal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Colorectal Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Colorectal Cancer Emerging Drugs Profile
* Lumakras (sotorasib): Amgen
Lumakras (sotorasib) is a highly selective inhibitor of KRAS G12C that potentially suppresses the rapid proliferation of cancer cells. Sotorasib forms an irreversible, covalent bond with the cysteine residue of KRAS G12C, holding the protein in its inactive form that blocks the oncogenic signaling. This results in apoptosis only in KRAS G12C tumor cell. It is being investigated as a treatment for a variety of solid tumors, including NSCLC, colorectal cancer and other solid tumor cancers. Currently, the drug is in the Phase III stage of its development for the treatment of Metastatic Colorectal Cancer.
* Axitinib: Pfizer
Axitinib is an oral therapy that is designed to inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3; these receptors can influence tumor growth, vascular angiogenesis and progression of cancer. In the U.S., INLYTA is approved for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. Currently, the drug is in the Phase II stage of its development for the treatment of Metastatic Colorectal Cancer.
* NX 1607: Nurix Therapeutics Inc
NX-1607 is an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types. NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models. Nurix is evaluating NX-1607 in an ongoing, Phase I dose escalation and expansion trial in adults with a variety of oncology indications at multiple clinical sites. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.
* TP-1454: Sumitomo Dainippon Pharma Oncology
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator that is currently being evaluated in a Phase I/I b study in patients with advanced metastatic or progressive solid tumors. TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.
Explore groundbreaking therapies and clinical trials in the Metastatic Colorectal Cancer Pipeline. Access DelveInsight's detailed report now! @ New Metastatic Colorectal Cancer Drugs [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic colorectal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Metastatic Colorectal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Metastatic Colorectal Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Colorectal Cancer Pipeline Report
* Coverage- Global
* Metastatic Colorectal Cancer Companies- Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech, and others.
* Metastatic Colorectal Cancer Therapies- Encorafenib, Cetuximab, NPX267, MRTX849, Cetuximab, TNO155, BXQ-350, and others.
* Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Metastatic Colorectal Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Metastatic Colorectal Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic colorectal cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic colorectal cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Metastatic colorectal cancer Collaboration Deals
* Late Stage Products (Phase III)
* Lumakras (sotorasib): Amgen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Axitinib: Pfizer
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* NX 1607: Nurix Therapeutics Inc
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic colorectal cancer Key Companies
* Metastatic colorectal cancer Key Products
* Metastatic colorectal cancer- Unmet Needs
* Metastatic colorectal cancer- Market Drivers and Barriers
* Metastatic colorectal cancer- Future Perspectives and Conclusion
* Metastatic Colorectal Cancer Analyst Views
* Metastatic Colorectal Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-colorectal-cancer-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Colorectal Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3692172 • Views: …
More Releases from ABNewswire
How to Choose the Right Tiling Contractor in Singapore: Top Companies to Conside …
Find the right tiling contractor in Singapore with our top company picks. Compare services, quality, and pricing, get expert help for your project today!
Choosing the right tiling contractor is an important decision when renovating your home or commercial space. A professional tile installation can improve the appearance, durability, and value of your property, while poor workmanship may lead to uneven tiles, damaged grout, water issues, and costly repairs.
With many Singapore…
Next.js vs Traditional Web Development in Singapore: Which Is Better? (FAQ Expla …
Compare Next.js vs traditional web development in Singapore. Explore key differences, benefits, and FAQs to choose the best solution for your website. Learn more!
At Averps Pte. Ltd., we specialize in next.js website development in Singapore, helping businesses choose the right technology for their digital platforms. Many business owners are unsure whether to use Next.js or traditional web development methods [https://www.google.com/maps?q=Next+js+or+traditional+web+development+methods&cid=9396342503762793240]. This guide explains the differences clearly so you can understand…
Best Print-On-Demand Service for Etsy Sellers: Printdoors Aligns Multi-Factory O …
Printdoors [https://www.printdoors.com/], an international customized supply chain platform, today introduced a targeted global fulfillment strategy engineered specifically for marketplace merchants. By structuring its industrial infrastructure to support compliance frameworks established by major digital platforms, Printdoors has launched an integrated workflow designed to eliminate order errors, maintain fulfillment transparency, and protect digital storefront ratings. The operational deployment combines real-time data integration with precise multi-factory scaling to support creative entrepreneurs navigating strict…
PoliceReport.info Simplifies the Missouri Uniform Crash Report and Form 1140 pro …
Plymouth, Massachusetts - PoliceReport.info, a trusted resource for obtaining official crash reports, has extended its comprehensive coverage to Missouri.
Our platform now serves all one thousand eighty one cities and counties across the state, delivering clear instructions on how to request a police report or accident report. Whether a collision occurs in St. Louis, Kansas City or a small rural community, we guide residents through the process with ease.
Missouri's crash reporting…
More Releases for Metastatic
Metastatic Uveal Melanoma Pipeline Analysis: Emerging Targeted and Immunotherape …
DelveInsight's Metastatic Uveal Melanoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline metastatic uveal melanoma therapies in various stages of clinical development. Major pharmaceutical and biotechnology companies are actively advancing innovative therapeutic strategies to address the high unmet need in metastatic uveal melanoma treatment.
Key takeaways from the Metastatic Uveal Melanoma Clinical Trial Landscape Report
• DelveInsight's metastatic uveal melanoma pipeline report depicts a growing therapeutic landscape with…
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
